Abstract
High dose chemo-radiotherapy with allogeneic bone marrow transplantation (BMT) is an effective therapy for patients with hematologic malignancies (1,2). The curative potential of this procedure is mediated in part by an immune mediated graft-versus-leukemia effect (3-8). Direct evidence of this effect is the reinduction of remission obtained after infusions of donor lymphocytes in patients who have relapsed after an allogeneic progenitor cell transplant.(9-13) Responses are more frequent in patients with chronic myelogenous leukemia (CML), but have also been observed in patients with acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), myeloma and lymphoma relapsing after allogeneic BMT (14-16).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Gale RP, Champlin RE. How does bone marrow transplantation cure leukemia? Lancet. 1984;2: 28–30.
Bortin M, Horowitz M, Gale R, et al: Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980’s. JAMA, 1992; 268: 607–612.
Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, The Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. NEJM. 1981;304: 1529–1533.
Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75: 555–562.
Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med. 1989;320: 828–834.
Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73: 1720–1728.
Goldman JM, Gale RP, Bortin MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion.. Ann Intern Med. 1988;108: 806–814.
Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med.1994;120: 646–652.
Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-vs-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.. Blood. 1995;86: 2041–2050.
Van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood. 1994;83: 3377–3383.
Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukeocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.. Blood. 1995;86: 1261–1268.
Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ, Goldman JM. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood. 1992;79: 1379–1381.
Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood. 1993;82: 2310–2318.
Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: Proof of principle. Blood. 1996;87: 1196–1198.
Rondon G, Giralt S, Huh Y, et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplantation. 1996;18: 669–672.
Collins R, Shpilberg O, Drobyski W, et al: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplant. J Clin Oncol, 1997; 15: 433–444.
Ferrara JL, Deeg HJ. Mechanisms of disease: Graft-versus-host disease. N Engl J Med. 1991;324: 667–674.
Holler E, Kolb H, Moller A, et al: Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation. Blood, 1990;7: 1011–1016.
Hill G, Crawford J, Cooke K, Brinson Y, Pan L, Ferrrara J: Total body irradiation and acute graft versus host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood, 1997; 90: 3204–3213.
Van Bekkum D: Conditioning regimens for marrow grafting. Semin Hematol, 1984;21: 81–90.
Yu C, Storb R, Mathey B, et al: DLA-identical bone marrow grafts after low dose total body irradiation: Effects of high dose corticosteroids and cyclosporine on engraftment. Blood, 1995; 86: 4376–4381.
Storb R, Yu C, Wagner J, et al: Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood, 1997; 89: 3048–3054.
Keating MJ, O’Brien S, Robertson LE, et al. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma. 1994;14 Suppl. 2: 11–16.
Keating M, Kantarjian H, Talpaz M, et al: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood, 1989; 74: 19–25.
Redman J, Cabanillas F, Velasquez W, et al: Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low grade lymphoma. J Clin Oncol, 1992; 10: 790–794.
Goodman E, Fiedor P, Fein S, et al: Fludarabine phosphate and 2 chlorodeoxyadenosine:Immuno-suppressive DNA synthesis inhibitors with potential application in islet allo-xenotransplantation. Transplantation Proc, 1995; 27: 3293–3294.
Plunkett W, Sanders P: Metabolism and action of purine nucleoside analogs. Pharmacol Ther, 1991; 49: 239–245.
Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11: 116–124.
Li L, Glassman A, Keating M, Stros M, Plunkett W, Yang L: Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res 1997; 57: 1487–1494.
Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993;9: 343–350.
Giralt S, Estey E, Van Besien K, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: harnessing graft-vs-leukemia without myeloablative therapy.. Blood 1997; 89(12): 4531–4536.
Giralt S, Gajewski J, Khouri I, et al: Induction of graft-vs-leukemia as primary treatment of chronic myelogenous leukemia: Blood 1997; 90: 418a.
Khouri I, Keating MJ, Przepiorka D, et al. Engraftment and induction of GVL with fludarabine-based non-ablative preparative regimen in patients with chronic lymphocytic leukemia.. Blood. 1996;88 (suppl l): 301a.
Bensinger W, Buckner C, Clift R, et al: A phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol 1992; 10: 1492–1497.
Bjorkstrand B, Ljungman P, Svensson H, et al: Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711–4718.
Lokhorst H, Schattenberg A, Cornelissen J, Thomas L, Verdonck L: Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206–4211.
Lokhurst K, Meuwissen O, Verdonck L, Dekker A, High risk multiple myeloma treated with high dose melphalan. J Clin Oncol 1992; 10: 47–51.
Slavin S, Nagler A, Naparstek E, et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.
Giralt S, Cohen A, Mehra R, et al: Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for conventional myeloablative conditioning. Blood 1997; 90: 417a.
Champlin R, Ho W, Gajewski J, et al. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood. 1990;76: 418–423.
Nimer SD, Giorgi J, Gajewski JL, et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation: A randomized controlled trial. Transplantation. 1994;57: 82–87.
Giralt S, Hester J, Huh Y, et al. CD8+ depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: graft vs leukemia without graft vs. host disease.. Blood. 1995;86: 4337–4343.
Alyea E, Soiffer R, Canning C, et al: Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998; 91: 3671–3680.
Bordignon C, Bonini C, Verzeletti S, et al. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor antitumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther. 1995;6: 813–819.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Giralt, S., Khouri, I., Champlin, R. (1999). Non Myeloablative “Mini Transplants”. In: Burt, R.K., Brush, M.M. (eds) Advances in Allogeneic Hematopoietic Stem Cell Transplantation. Cancer Treatment and Research, vol 101. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4987-1_5
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4987-1_5
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7264-6
Online ISBN: 978-1-4615-4987-1
eBook Packages: Springer Book Archive